Focus Stocks
Is WellPoint Ready for a Break Out?
Published on Thursday, 20 December 2012 06:28 Written by TradersHuddle Wire
New York, December 20th (TradersHuddle.com) - WellPoint Inc. (NYSE:WLP) closed the trading day at $59.97, near its 50 day and 200 day moving averages set at $58.78 and $62.64 respectively. WellPoint's price action placed the stock above the 50 day moving average but below its 200 day moving average, providing a nice trading setup with clear reference points.
WellPoint Inc. (NYSE:WLP) is a health benefits company. The Company provides health, dental and vision benefits, pharmacy benefits, life insurance, and life and disability insurance benefits. WellPoint operations include Blue Cross and Blue Shield plans.
WellPoint seems to be setting up for a tight range between the 50 day moving average as support and the 200 day moving average serving as resistance.
A tiered approach appears to be the best way to maximize possible movements in the stock, as traders could establish a small position in WellPoint and wait for the stock to break out above the 200 day moving average at $62.64. Then they could add to the position as momentum builds with the breakout. On the other hand, if support being referenced at the 50 day moving average set at $58.78 breaks, it could signal further downside for WellPoint in the horizon.
Related Articles
- WellPoint Is Near a Key Resistance Area
- Trading Idea: Key levels for WellPoint
- WellPoint Is Close to Resistance
- Is WellPoint Closing in to Support?
- WellPoint Is Close to its 50 Day Moving Average
- Trading Idea: - Is WellPoint close to Resistance?
- Is WellPoint Closing in to Resistance?
- WellPoint Is Near Resistance
- WellPoint Is Close to Resistance
- Trading Idea: What to Expect as WellPoint Breaks Resistance
Related Partner Headlines
- WellPoint Inc Stock Buy Recommendation Reiterated (WLP) - TheStreet.com
- WellPoint Inc Stock Buy Recommendation Reiterated (WLP) - TheStreet.com
- WellPoint Inc (WLP): Today's Featured Health Services Laggard - TheStreet.com
- UPDATE: Bank of America Downgrades WellPoint to Underperform on Election Outcome - Benzinga
- Wellpoint Third Quarter Earnings - Investopedia
- UPDATE: WellPoint Posts Rise In Q3 Profit, Lowers Full-Year Revenue Forecast - Benzinga
- WellPoint Third Quarter Earnings Preview - Investopedia
- WellPoint Inc Stock Buy Recommendation Reiterated (WLP) - TheStreet.com
- WellPoint Inc (WLP): Today's Featured Health Services Winner - TheStreet.com
- WellPoint Inc (WLP): Today's Featured Health Services Winner - TheStreet.com
TradersHuddle Search
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Dow Today: Verizon Communications (VZ) Higher - TheStreet.com -
Separating the Bargains From the Busts - TheStreet.com -
Cramer Quick Take: The 60-Inch TV Will Be Key This Holiday - TheStreet.com -
Cramer Quick Take: Cisco Wins If Fiscal Cliff Is Resolved - TheStreet.com -
Gap Up and Sit - TheStreet.com -
Apple, Intel, MicroStrategy: Tech Winners & Losers - TheStreet.com -
Windows 8 PC Sales Disappointing: Report - TheStreet.com -
Cramer Quick Take: Buy Home Depot and Lowe's - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:15,112.19 Trade time:4:52PM EDT Value change:▼206.04 (-1.35%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,628.93 Trade time:4:52PM EDT Value change:▼22.88 (-1.39%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:3,443.20 Trade time:5:15PM EDT Value change:▼38.98 (-1.12%)In The Wires
-
Lender Processing Services, Inc. Announces an Adjustment to the Consideration Mix in Its Acquisition by Fidelity National Financial, Inc. -
U.S. Market Cap Guidelines Updated and Several Constituent Changes Announced for the S&P SmallCap 600 -
Timbercreek Mortgage Investment Corporation June 2013 Dividend -
Timbercreek Senior Mortgage Investment Corporation June 2013 Dividend -
Timbercreek Global Real Estate Fund Announces Second Quarter Distribution for 2013 -
The Swiss Helvetia Fund, Inc. Declares Income And Capital Gain Distributions -
Wowjoint Holdings Limited Reports Fourth Quarter & Fiscal Year 2012 Financial Results -
Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine








